Introduction
Optimal long-term antithrombotic treatment of patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) is unresolved, and common practice is to add antiplatelet therapy to oral anticoagulation (OAC). The cornerstone of AF treatment should include OAC if one or more stroke risk factors (such as vascular disease) are present 1 , while initial preventive treatment after myocardial infarction (MI) or percutaneous coronary intervention (PCI) consists of drugs for platelet anti-aggregation.
2 American and European consensus documents (Level C evidence) recommend adding two antiplatelet drugs on top of vitamin K antagonist (VKA) arbitrarily from 1 month to 1 year after an acute coronary event depending on degree of severity, type of stent implanted, and presumed bleeding risk. 3, 4 The risk of serious bleeding with multiple antithrombotic drugs is raised substantially 5, 6 , even with only short-term initial therapy 7 . For this reason, one antiplatelet should be removed when the risk of recurrent coronary event and stent thrombosis has declined, and VKA alone is now recommended in AF patients who are greater than one year from an acute coronary event or revascularization procedure. 8 New data also suggest that MI risk could actually increase with multiple antiplatelets added on top of OAC treatment. 9 Both the need for additional antiplatelet after the vulnerable period and the timing of VKA monotherapy are unknown. In 'real-life' AF patients surviving an acute coronary event, we investigated ongoing antithrombotic treatment and risk of new coronary events, thromboembolism and serious bleeding. We tested the hypothesis that long-term antithrombotic treatment with only VKA after 12 months with stable CAD compared to adding a single antiplatelet agent to VKA results in fewer serious bleeding events but without an additional cost of increased risk of recurrent coronary events or thromboembolism.
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Methods

Databases
From nationwide Danish administrative registries, we extracted information on healthcare and drug utilization that could be linked on the individual level to each resident. 10 All admissions to hospitals are recorded by the National Patient Registry and provided by International
Classification of Diseases (ICD) coding (ICD-8 until 1994 and ICD-10 onwards). Diagnoses of MI (predictive value 94%) 11 , AF (predictive value 99%) 12 and ischemic stroke (predictive value 97%) 13 have been validated, and bleeding diagnoses have shown a positive predictive value of 89-99% in hospital databases. 14 The Danish Registry of Medicinal Product Statistics (national prescription registry) provides data on number of tablets, the strength and the date of dispensing for all prescribed drugs classified according to the Anatomical Therapeutic Classification (ATC).
Vital status and causes of death are obtainable through the civil registration system and the National Causes of Death Registry, respectively. The latter provides information from physicians on both the primary and potential contributing causes of death also according to the ICD-10
classification. All ICD and ATC codes used in the study are listed in Supplemental Table 1 and   Supplemental Table 2 .
Population
All AF patients hospitalized for either MI or PCI between January 1, 2001 and December 31, 2011 were identified. To be eligible for inclusion, no subsequent hospitalization for MI, unstable or stable angina within 360 days was allowed (Figure 1) . Patients with AF and stable CAD, defined as 360 days from index coronary event (MI/PCI), were followed from 2002 through the end of the study period on December 31st 2011. Only patients prescribed antithrombotic therapy were included. To ensure no recent MI/PCI episode occurred prior to an AF diagnosis, patients prescription registry) provides data on number of tablets, the stre a ngth and the dat at te e of of o d d dis is ispe pe pens ns nsin ing g for all prescribed drugs classified according to the Anatomical Therapeutic Classification (ATC)
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Antithrombotic treatment regimens
We defined the following antithrombotic treatment regimens: single antiplatelet therapy (aspirin or clopidogrel), VKA monotherapy (warfarin or phenprocoumon), dual antiplatelet therapy (aspirin and clopidogrel), VKA plus single antiplatelet (either aspirin or clopidogrel), and VKA plus dual antiplatelet therapy., We calculated drug availability at any given time from claimed prescriptions, as previously described [5] [6] [7] . A daily dosage was calculated for up to three prescription claims, allowing the daily dose (for VKA only) to change with prescriptions claimed. A fixed dosing regimen was used for aspirin (75, 100 and 150 mg) and clopidogrel (75 mg). Treatment at the date of inclusion was defined as baseline treatment.
Outcomes
Effectiveness outcomes were defined as MI/coronary death and fatal/nonfatal thromboemblism.
Thromboembolism included ischaemic stroke and systemic arterial embolism. The principal safety outcome was fatal/nonfatal bleeding. A secondary outcome of all-cause death was also defined. Nonfatal events were obtained from admissions in the National Patient Registry, and fatal events were recorded from National Causes of Death Register. The diagnoses (e.g.
intracranial bleeding, gastrointestinal bleeding, anemia from bleeding) to characterize 'serious bleeding' has previously been used. [5] [6] [7] This category of serious bleeding would include most ISTH (International Society of Thrombosis and Haemostasis) major and clinically relevant nonmajor bleeds, although all events required hospitalisation. 15 For additional insight, we also categorized death from bleeding as fatal bleeding directly and as death within 30 days from a nonfatal bleeding admission. A composite outcome of MI, thromboembolism, bleeding and allclaimed. A fixed dosing regimen was used for aspirin (75, 100 and 150 mg) and d c c clo o opi pido do dogr gr grel el el ( (7 75 mg). Treatment at the date of inclusion was defined as baseline treatment.
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Concomitant treatment and comorbidity
Prescription claims 180 days prior to inclusion defined concomitant pharmocotherapy, and comorbidities were determined from any preceding diagnosis as previously described 16 
Statistical analyses
Characteristics according to antithrombotic treatment at inclusion are expressed as percentages or as means and standard deviations (SD). Rates were all crude incidence rates, calculated by the the number of events per 100 person-years with 95% CI (confidence interval). The risk of outcomes associated with antithrombotic treatment was estimated by means of time-dependent Cox proportional-hazards models, with adjustment for changes in exposure (based on prescription claims) during follow-up. VKA as monotherapy was used as reference. All models were adjusted for age, gender, inclusion year and MI/PCI status at index event, pharmacotherapy and comorbidity (including factors comprising the CHA 2 DS 2 -VASc and HAS-BLED scores).
Unadjusted estimates were also reported for the main models. To assess if the risk of our effectiveness or safety outcomes changed over time, we performed landmark analyses for antiplatelet therapy was omitted from the HAS-BLED score because it is an exp pla la ana na ato to ory ry ry variable. The scores have been shown to accurately predict risk of thromboembolism and bl lee ee edi di din ng ng i i in n n th th the Da Da Dani ni n sh population.
17
S St Stat at tis i tical an nal aly y yse e es
Ch Ch har ar a ac ac acte teri rist st stic ic ics s a a acc co cord rd din in ng g g to t a a ant nt tit it ith h hro ro romb mb bot ot otic ic ic t tre e eat at a me me men nt a at t in in inc c clus us usio io on n ar ar are e e ex exp pr pres es sse se ed d as as as p p per r rce ce ent ntag ag age es s or as means an an nd d d st st tan an anda da dard rd r d d dev ev evia iati ti tion on o s s s (S (S SD) D) D). . Ra Ra Rate te tes s we we w re re r a a all ll ll c c cru ru rude de de i i inc nc ncid id iden en ence ce ce r r rat at a es es s, , ca ca calc lc lcul ul u ated by the e e periods of 0-2 years and >2 years from inclusion in a Cox model for each outcome. Due to low numbers, only aspirin monotherapy, dual antiplatelet, VKA plus aspirin and VKA plus clopidogrel were explored. We also decided to report risks for patients that had a previous PCI performed at their index event to assess if longer term outcomes differed for patients receiving invasive intervention (considered "low-risk" patients) compared to patients receiving only pharmacotherapy (considered "high-risk" patients). We performed a sensitivity analysis as suggested by Schneeweiss for assessing the impact of a potential unmeasured confounder for regimens of VKA and VKA plus aspirin as these were the most prevalent regimens including VKA and assessing the relation of adding antiplatelet to VKA was our main purpose. 18 All patients were followed to death or the end of the study period (December 31, 2011). We tested for fulfilment of proportional hazards assumption, linearity of continuous variables and lack of interactions for the Cox models, and no significant deviations from the assumptions were found.
A two-sided P value of less than 0.05 was considered to indicate statistical significance. Data were analysed with SAS 9.2 (SAS Institute Corp, Cary, NC) and Stata 11.0 (StataCorp, College Station, TX).
Ethics
Ethical approval is not required for register-based studies in Denmark. The Danish Data protection agency approved the study (reference no. 2007-58-0015 / I.suite no. 00916 GEH-2010-001). Anonymized data were made available to us so individuals could not be identified.
Results
In 8,700 AF patients with stable CAD (mean age 74.2, SD 10.4; 38% female) included in the study, a total of 3,243 (37%) were treated with VKA at inclusion ( Table 1) . Selection of the patients were followed to death or the end of the study period (December 31, 20 01 1 11). ). . W W We e te te test st sted ed f for fulfilment of proportional hazards assumption, linearity of continuous variables and lack of n nte te era ra ract ct cti io ions ns ns f f fo or t the he he C Cox models, and no significan an ant d deviations from om m the he e a a as ssumptions were found. and 1,061 (12%), respectively. Corresponding crude incidence rates were 7.2, 3.8 and 4.0 events per 100 person-years. Table 2 shows the numbers and crude incidence rates for each outcome according to antithrombotic treatment group. Crude incidence rates of MI/coronary death were similar for VKA and VKA plus aspirin but higher for VKA plus dual antiplatelet therapy.
Adjusted HRs for all outcomes are illustrated in Figure 3A -D. Relative to VKA monotherapy, there was no decrease in risk of MI/coronary death associated with use of VKA plus single antiplatelet (either aspirin or clopidogrel), and a higher risk with dual antiplatelet therapy with or without VKA. A comparable risk of thromboembolism was present for regimens including VKA, while non-VKA therapies were associated with greater risk compared to VKA monotherapy.
Bleeding risk was greater in those who also took antiplatelets (either aspirin or clopidogrel).
Aspirin monotherapy showed a decrease in bleeding risk while clopidogrel (with or without aspirin) showed comparable bleeding risk compared to VKA as monotherapy. The unadjusted HR estimates are provided as supplementary material (Supplemental Table 3 ), and resemble the adjusted analyses. The combined outcome of MI, thromboembolism, bleeding and all-cause mortality showed no beneficial effect of VKA plus a single antiplatelet compared to VKA per 100 person-years. Table 2 shows the numbers and crude incidence rates for e e eac c ch h h ou ou outc tc tcom om ome e according to antithrombotic treatment group. Crude incidence rates of MI/coronary death were Table 3) .
Previous PCI, landmark analyses, death from bleeding and sensitivity analysis patients not experiencing bleeding, 2,950 died (38%), corresponding to a HR 2.14 (1.94-2.37).
No significant difference was observed of death from bleeding between VKA and VKA plus single antiplatelet, and only VKA plus dual antiplatelet therapy was associated with significantly increased risk in death from bleeding (Supplemental Table 5 ). When estimating the impact of an unmeasured confounder, we found that a potential confounder should be three times more prevalent in the exposed group (VKA + aspirin) and be associated with a three-fold increase in risk of the outcome to explain a beneficial effect of VKA + aspirin compared to VKA concerning the outcome of MI. Regarding outcomes of thromboembolism, serious bleeding and all-cause hrombosis between VKA with and without single antiplatelet therapy, while blee ee edi di ing ng g r ris is sk k k wa wa w s greater in those who also took an antiplatelet (either aspirin or clopidogrel). 951 patients a a adm dm dmit it tte te ted d wi wi w th h h a a a n n non on nfa fa f ta ta al l bl bl blee ee edi di ding ng ng ep ep epis is sod od ode, , 5 5 507 07 07 d d die ie ied d d (5 5 53% 3% 3%) ) ) wh wh whil il i e e in in in t t the he he 7 7,749 death, corresponding analyses indicated that an unmeasured confounder should be very unevenly distributed in the groups with a very strong association towards VKA plus aspirin therapy, and also be very strongly associated with the outcome.
Discussion
In this nationwide observational study, the addition of antiplatelet therapy to VKA in patients with AF and stable CAD was not associated with any benefit while serious bleeding was significantly increased. Therapies only including antiplatelet drugs (and not VKA therapy) were associated with an increased risk of all-cause death, with an appreciable risk of bleeding with the combination of aspirin and clopidogrel therapy. The study suggests that monotherapy with VKA may be the best choice in patients with AF and stable CAD.
Randomized clinical trials have demonstrated that treatment with single and dual antiplatelet therapy is valuable after an MI and after a PCI procedure. 19, 20 There is also evidence from randomized trials for the benefit of long-term VKA therapy in selected patients with AF. 21 We and others have previously examined the use of single and multiple antithrombotic therapies after a recent coronary event. 6, 22, 23 However, there is lack of evidence for optimal long-term antithrombotic treatment strategy in patients with AF and stable CAD.
The ineffectiveness of dual antiplatelet therapy on recurrent MI risk compared to VKA monotherapy is somewhat unexpected and was also present in patients treated with PCI. Due to the non-randomized design of the study, this association could be based on the assumption that antiplatelet users were found ineligible for treatment with VKA and INR monitoring, and most likely comprise a group with a poorer outcome profile. A possible mechanistic explanation is that increased thrombogenesis in AF could play a role. AF has often been described as a combination of aspirin and clopidogrel therapy. The study suggests that monoth he er erap p py y wi wi with th th V V VK KA a may be the best choice in patients with AF and stable CAD.
Ra Ra Rand nd ndo om omiz iz ze ed ed clinical trials have demonst t tra ra r te ed that treatmen en ent wi wi ith th th single and dual an nti i ip platelet the era ra apy y y i is s va va al lu luab ab able le le a aft ft te e er r r an an n M M MI a an and d d af fte ter r a PC PC PCI I pr pr proc oce ed edu ur ure. e 19 19 , 1 2 2 20 T T The he here re i i is s s al al a so so o e e evi v vide de d n n nce fr rom om om r r ran an a do do omi mi m ze zed d d t tr tria ial ls s f f for or th he he b b ben en enef ef efit it o of f f lo lo lon ng ng-t -t -te e erm rm m V VKA KA KA t t th h hera ra rapy py y i i in n n se se el lec ct cted ed d p p pat at a ie ie ent nt nts w w wit th th A A AF. . 21 We and other ers s s ha ha h ve ve ve p p pre re r vi v v ou ou ousl sl sly ex ex exam am min n ned ed ed t t the he h u u us s se e e of of of s s sin ingl gl gle e e an an and d d mu m m lt lt ltip ip iple le le a a ant nt ntit it i hr hr hrom om ombo bo boti ti t c therapies s s prothrombotic state, and while underlying mechanisms are not fully understood, clots (including coronary) in these patients could be fibrin rich (rather than platelet rich) leading to a more protective effect of anticoagulation. 24 The Although the Thrombosis Prevention Trial focused on primary prevention of coronary events in high-risk subjects comparing the effect of low-intensity warfarin against aspirin, the investigators concluded that warfarin per se reduced fatal coronary events compared to aspirin but the combination of both was most effective in primary prevention of ischemic heart disease. 26 The Warfarin-Aspirin Reinfarction (WARIS) II study investigated the effect of aspirin, warfarin or both for secondary prevention after MI, and found warfarin alone or with aspirin to be superior to aspirin alone for a combined endpoint of death, nonfatal reinfarction and stroke. 22 anticoagulant therapy in patients with oral anticoagulation and coronary StenTin ng g) g), , fo foun un und d d a a a ignificant increased risk of death and numerical more events of MI in VKA plus dual an nti ti ipl pl plat at at l el elet et et ( ( (a a aspi piri ri rin n n and clopidogrel) compared to to to V V VKA plus clopi pi ido d gr gr rel el el t therapy 9 . Our data u upp p pport these fi fi ind n n i i ings gs s, i. i. .e. e t t tha ha hat t t a ant nt ntip ip ipla late tel let t th he e erap py y a alon on ne e e or or r t a a add dde ed ed o on n t to top p p of of f V V VKA KA A i is s s no no ot r as sso so soci ci ciat at a ed ed w w wi it ith h f fu fur rt rthe her r p pr prot o ec ec cti ti ion on on a a ag ga gain in nst st st t t th hr hrom om ombo bo os si is. H H How ow owev ev ver er e , , as as s a a an n ob ob bse serv rv rvat at atio iona na nal l l st tud ud udy y a a causal treatme me ent nt nt e e eff ff ffec ec e t t t ca c c nn nn nnot ot ot b b be e e es es esta ta t bl bl lis is i he he hed. d. d. F F Fu urt rt r he he her r r st t tud ud udie ie ies s s ar ar are e e wa wa warr rr ran an ante te ted d d to to e e exp xp xplo lo lore re r this However, when comparing warfarin versus warfarin plus aspirin, no difference in either the combined endpoint or in event-free survival was demonstrated. For only reinfarctions, there was a significant protective effect of warfarin monotherapy and warfarin plus aspirin compared to aspirin only, but no analyses on reinfarctions were given for warfarin versus warfarin plus aspirin. This latter issue is important in patients with coronary artery disease and co-existing AF where oral anticoagulant is needed for thromboprophylaxis, and warfarin could also protect against MI.
We confirmed previous results for inadequacy of single or dual antiplatelets compared to VKA 25 , and furthermore showed that any addition of antiplatelets to VKA did not result in additional thromboembolic protection. Notably, bleeding risk was increased with more intense antithrombotic treatment, and in accordance with previous studies we found a significant increase for VKA plus single antiplatelet relative to VKA only. 27 In peripheral artery disease, the combination of VKA plus aspirin had no benefit on thromboembolism but substantially increased the risk of major bleeding. 28 Although a bleeding episode raised subsequent risk of death more than two-fold, we did not find a difference in death from bleeding when adding a single antiplatelet to VKA. Hence, adding an antiplatelet agent to VKA agents does not add any benefit concerning preventing thrombosis but, notably, is associated with an increased risk of bleeding.
Long-term secondary prevention of CAD with aspirin is recommended in most patients (without AF). Still, interpretation of data on aspirin use in primary prevention has linked aspirin to poorer prognosis and associated aspirin with sudden death, hence masking MI events 29, 30 .
Also, the main benefit of aspirin on mortality post-MI is seen early (<30 days) after which the event free survival curves for aspirin and placebo are comparable. 19 However, many of these additional thromboembolic protection. Notably, bleeding risk was increased with th h m m mor ore e in in nte te tens ns n e e antithrombotic treatment, and in accordance with previous studies we found a significant n ncr cr rea ea eas se se f f for or or V V VKA KA A p p plu l s single antiplatelet relative ve e to o o VKA only. 27 I I In pe pe eri ri rip p pheral artery disease, the co om mb mbination of of f V V VKA KA KA p plu lu us s s as as aspi pi piri rin n ha ha had d no no o be en ne e efit on on on thr hr ro om ombo b boe em emb bo boli lism sm b but ut s s sub ub ubst stan an anti ti tial al ally ly l n ncr cr crea ea ase se s d d th th the e e ri risk sk k o o of f m ma maj jo jor r bl bl lee eedi di ding ng ng. 28 A A Alt lt ltho ho houg ug gh h h a a a b bl blee ee edi di ding ng ng e epi pi piso so ode de de r ra ai i ise ed ed s s sub ub ubse se s qu qu que e ent t r ris sk sk o o of death more t tha ha han n n tw tw wo-o-o fo fo f ld l l , we we we d did id id n not ot o f f fin in ind d d a a a di di diff ff ffer er eren en ence ce c i i in n n de de deat at ath h h fr fr from m m b b ble le leed ed edin in ing g wh wh when en en a a adding a older studies were in the era prior to contemporary management of acute coronary syndrome with early coronary intervention and use of stents and other secondary prevention measures such as statins, renin-angiotensin system inhibitors etc. For the primary outcomes, crude rates were lower in patients treated with PCI compared to non-PCI treated. In either group, the findings from the adjusted analyses resembled those from the main analyses. Also, the protective effect of VKA on thrombosis was unchanged after two years compared to VKA plus a single antiplatelet agent.
For the indication of stroke prophylaxis in AF, all approved new oral anticoagulants (e.g.
apixiban, rivaroxiban, dabigatran) show similar or better overall effect compared to VKA. 31 Even with these new anticoagulants, combination therapy is associated with greater bleeding risk and no appreciable effect on thromboembolism. 32 Whether these new anticoagulants can replace VKA in AF patients with co-existing CAD is unknown and further investigation is warranted. Of note, recent data support dabigatran could increase MI risk compared to warfarin.
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Clinical implications
While the current study is purely observational, some of the conclusions are backed by a subgroup analysis of the ACTIVE W trial and the recent WOEST trial described above. Given that there is no evidence of benefit from long-term combination of VKA with platelet inhibition, but certainty of some risk with bleeding, we find that using VKA only in patients with AF, an indication for VKA and stable CAD is a valid consideration.
Strengths and limitations
This observational nationwide study includes real-life unselected cohort of patients with AF and CAD, which is often characterized by being at higher risk for adverse events compared to controlled trials which often apply restrictive inclusions criteria for subjects that make Even with these new anticoagulants, combination therapy is associated with grea at ater r r b ble le leed ed edin in ing g g r risk
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Conclusions
In AF patients with stable CAD, adding antiplatelet therapy (either aspirin or clopidogrel) on top of VKA is not associated with a greater reduction in risk of recurrent coronary events or thromboembolism, while risk of bleeding is significantly increased. Thus, VKA might be considered as monotherapy for AF patients after 12 months of a coronary event among patients antiplatelet therapy. Possible unmeasured confounders were smoking status, bod dy y y ma m m ss ss ss i i ind nd ndex ex e , , nformation on coronary anatomy, type of AF (i.e. paroxysmal, persistent, or permanent), INR va alu lu ues es s a and nd nd p p pa a atie ent nt nt/ /p /physician preference for VKA A A th h herapy. The es sti ti t m a at atio io ion n n of the impact of a pote e en ntial unme meas as su ur red ed d c co on onfo fo foun un und de der r on on n t the he out t tco o ome es r i inv ve es st stig ig gat ated ed s su ug gge ges s sts s th ha at at s suc uch h h a a a co co onf f fo ou ound nd nder e ve very ry ry u u unl nl n ik ikel el ely y y al alo on one e e co co oul ul ld d ha hav ve v d d dri ri rive v ven n th th the e e re re resu u ult lt lt T The he reg eg egis is istr try y y ho ho old ld ds s s no no o d d dat ata a a on on n t typ yp ype e e of of f s ste tent nt t s. s.
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